top of page

WE LIKE TO SHARE OUR GOOD NEWS WITH YOU AND THE WORLD. PLEASE FIND ALL OUR PRESS RELEASES HERE:

NOVEMBER 2025

VESPER BIO SECURES STRATEGIC INVESTMENT FROM THE ALZHEIMER’S DRUG DISCOVERY FOUNDATION AND THE ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION THROUGH THEIR TREAT FTD FUND

digital-download-pyramidal-neuron-anatomy-art_edited.jpg

OCTOBER 2025

VESPER BIO ANNOUNCES POSITIVE PHASE IB/IIA TOPLINE RESULTS FOR LEAD CANDIDATE VES001 FOR FRONTOTEMPORAL DEGENERATION

digital-download-hands-reassurance-art.jpg

JULY 2025

JACOB FALCK HANSEN APPOINTED AS CHIEF EXECUTIVE OFFICER OF VESPER BIO 

neurons-art-brain-sell-digital-download-colorful.jpg

MAY 2025

VESPER BIO ACHIEVES ENROLMENT MILESTONE IN PHASE IB/IIA TRIAL OF LEAD CANDIDATE VES001 FOR FRONTOTEMPORAL DEMENTIA.

neuron-art-brain-sell-colorful-digital-download.jpg

JANUARY 2025

VESPER BIO INITIATES PHASE IB/IIA PROOF OF CONCEPT STUDY OF VES001 IN ASYMPTOMATIC PATIENTS WITH GENE MUTATIONS THAT CAUSE FRONTOTEMPORAL DEMENTIA (FTD).

medicine-wheel-digital-download.jpg

SEPTEMBER 2024

VESPER BIO ANNOUNCES SUCCESSFUL PHASE I STUDY FOR POTENTIALLY DISEASE-MODIFYING TREATMENT FOR FRONTOTEMPORAL DEMENTIA.

digital-download-multipolar-neurons-art.jpg

MAY 2024

VESPER BIO ANNOUNCES COMPLETION OF SINGLE ASCENDING DOSE STAGE IN TRIAL OF ITS LEAD CANDIDATE VES001.

colorful-brain-anatomy-art-digital-download.jpg

JANUARY 2024

VESPER BIO AWARDED GRANT BY THE MICHAEL J. FOX FOUNDATION TO ASSESS SORTILIN INHIBITORS IN THE TREATMENT OF PARKINSON’S DISEASE.

digital-download-pyramidal-neuron-anatomy-art_edited.jpg

DECEMBER 2023

PHASE I STUDY UNDERWAY AS FIRST VOLUNTEER DOSED WITH VES001, A FIRST-IN-CLASS ORAL TREATMENT FOR FRONTOTEMPORAL DEMENTIA.

digital-download-hands-reassurance-art.jpg

Website by KC STUDIO

bottom of page